Hovione is committed to doing its part for a better world.
Loures, Portugal, January 12th, 2015 – Hovione today announced the appointment of Dr. Filipe Gaspar as Vice President of its Research and Development organization. Dr. Gaspar will lead teams based in Lisbon and New Jersey that serve our clients’ drug development projects; he will also be defining long-term product development strategies and collaborations. He will report to Guy Villax, Hovione’s Chief Executive.
“We are very pleased to have Filipe running our R&D. Filipe brings great science and leadership skills. For the last 10 years Filipe has been the driving force behind our Particle Engineering, and if we have four new drugs today on the market it is because he and his team made sure we had the right capabilities, knowhow and ability to deliver” said Guy Villax.
“I am honored to have the opportunity to lead this talented R&D team and help fulfilling our mission of serving our customers developing and delivering innovative medicines for patients”, said Filipe Gaspar.
Dr. Gaspar is the co-author and co-inventor of numerous publications, scientific presentations and patents. He is a Chemical Engineer from Instituto Superior Técnico (Lisbon) and has a PhD in Chemical Engineering from the University of Birmingham.
Dr. Gaspar joined Hovione in 2003 as a Manufacturing engineer and later became responsible for the technical leadership of spray drying technology. In 2004 Dr. Gaspar moved to R&D to start the Particle Engineering group, there he was involved in more than 120 projects from preclinical stage to commercial. During that period he was the Lead Scientist in four projects that reached commercial stage, including the first at Hovione submitted under Quality by Design. He was instrumental in many of the projects that contribute to Hovione’s growing success in Particle Engineering. In 2012 he moved to a Business Development role and spent a year based in New Jersey.
Hovione is an international company with over 50 years’ experience in the development and compliant manufacture of Active Pharmaceutical Ingredients and Drug Product Intermediates. With four FDA inspected sites in the U.S., China, Ireland, and Portugal, the company focuses on the most demanding customers, in the most regulated markets. In the last 5 years it stood behind 1-2 NDA approvals each year, and its DMFs and CEPs are referenced in dozens of ANDAs and marketing authorization that are approved each year. The company also offers branded pharmaceutical customers services for the development and compliant manufacture of innovative new drugs. It is able to support highly potent compounds and offers proprietary product development and licensing opportunities for drug products. In the inhalation area, Hovione is the only independent company offering such a broad range of services.